
    
      After obtaining approval from the ethics committee and informed consent, a total of 90
      patients aged 18-70 years, conscious (GCS>13) and American Society of Anesthesiologists (ASA)
      class I-III, who had intracranial shift >0.5 cm or glioblastoma multiforme or metastatic
      tumor and who were scheduled for supratentorial mass resection under elective conditions,
      will be included in the present prospective, randomized, double-blind and placebo-controlled
      study. Patients with heart failure, kidney insufficiency, diabetes insipidus, electrolyte
      imbalance and who are unconscious will be excluded from the study.

      The patients will randomized into 3 groups:

      Group 1: %3 HS bolus 3 mL.kg-1 Group 2: %3 HS infusion 20 ml/h Group 3: %20 mannitol 0,6
      gr.kg-1 After head fixation, all patients will be administered with HS or mannitol (over 20
      minutes). Arterial blood gas (ABG) analysis (Cobas b 221 blood gas analyzer, RocheÂ®, Basel,
      Switzerland) will be made at 30 minute,2,4,6,8. hours. Blood sodium, potassium, chlorine,
      base excess, lactate levels and blood osmolarity will be recorded in each time intervals. The
      brain relaxation scale will be recorded at the time of dura opening.
    
  